Suppression of Oral HHV8 Shedding With Valganciclovir
Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir
Sponsor: Hoffmann-La Roche
A PHASE2 clinical study on Human Herpesvirus 8, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Dec 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .